Table 3.
The relationship between tumor response and occurrence of CRP-AFP model in patients treated with PD-1 inhibitors.
| Treatment response | CRP-AFP model | p | ||
|---|---|---|---|---|
| Low-riskgroup (n = 38) | Intermediate-risk group (n = 43) | High-risk group (n = 20) | ||
| CR | 1 (2.6) | 0 (0.0) | 0 (0.0) | |
| PR | 4 (10.5) | 5 (11.6) | 1 (5.0) | |
| SD | 26 (68.4) | 23 (53.5) | 6 (30.0) | |
| PD | 7 (18.4) | 15 (34.9) | 13 (65.0) | |
| ORR (CR+PR) | 5 (13.2) | 5 (11.6) | 1 (5.0) | 0.625 |
| DCR (CR+PR+SD) | 31 (81.6) | 28 (65.1) | 7 (35.0) | 0.002 |
Variables are expressed as number of patients (%).
AFP, alpha-fetoprotein; CR, complete response; CRP, C-reactive protein; DCR, disease control rate; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease.